Introduction: what is actually the question?
Cancer can arise from either stem or committed cells. [1] [2] [3] [4] [5] [6] [7] That can be both ways. The question is not whether tumor stem cells exist. Tumor stem cells for myeloid leukemia, breast, lung, and brain cancers have been isolated and characterized. 1, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The question is whether stem cells cause therapeutic failure, and whether therapy should target resting stem cells or any resting cells for that matter.
Stem cells and cell lines
Stem cells resident in adult tissues are principally quiescent, yet harbor enormous capacity for self-renewal and for replenishing their tissue constituents. 1, 6, 16, 20 By asymmetric division, one stem cell produces one stem cell and one cell that in turn produces rapidly proliferating progenitor cells, committed to differentiation ( Figure 1 ). While progeny rapidly proliferate, stem cells are quiescent most of the time. 16, [20] [21] [22] [23] Key features of normal stem cells are quiescence, asymmetric division, and multipotency. Progenitors undergo a limited number of cell divisions and then differentiate and/or die. Thus, separating self-renewal and proliferation, normal tissues contain (a) resting stem cells and (b) proliferating cells with limited self-renewal, and (c) terminal cells: either resting differentiated cells or apoptotic cells (Figure 1 ). If oncogenic mutation occurs in a stem cell, it may become a tumor stem cell, thus sustaining tumor instead of normal tissue. Importantly, even if an oncogenic mutation occurs in stem cells, it may be manifested in proliferating progenitor cells. For example, the chromosomal translocation Bcr-Abl occurs in hematopoietic stem cells. 24 Bcr-Abl reveals its oncogenic potential in proliferating cells, thus causing chronic myeloid leukemia (CML). Only myeloid proliferating cells are expanded in CML. 24 Thus, in CML, leukemic stem cells (with Bcr-Abl) produce leukemic blast cells, which proliferate and then may differentiate to mature blood cells ( Figure 1 ).
Mutations in proliferating progenitor cells will be eliminated, unless such mutations render cells immortal (or block differentiation and/or apoptosis). During tumor progression, proliferating cells eventually acquire the self-renewal capacity, while losing the ability to differentiate. For example, in blast crisis of CML, additional mutations occur in cycling progenitor cells, rendering them capable to sustain leukemia. 25 Oncogenic mutations such as activation of telomerase and b-catenin or loss of Rb and p53 increase self-renewal. Proliferation and immortality merge in one malignant cell. Either stem cells become proliferating or proliferating cells become immortal. 1, 2, 6, 15, [25] [26] [27] In this new hierarchy, a self-renewing clone (Figure 2 CL) is analogous to a cell line (CL). In a cell line in vitro, each cell undergoes symmetric division, thus simultaneously renewing itself. Typically, each cell can originate a clone (e.g., by limiting dilution). Some cell lines (e.g., HL60) have low clonogenic efficiency, because they just do not grow well as single cells (e.g., HL60 cells are dependent on conditioned medium). It should be noted that, in cell lines, cells are selected for proliferation and self-renewal in optimal cell culture conditions, rather than for the ability to grow from a single cell (e.g., clonogenicity and/or tumorigenicity). In vitro, the stem cell hierarchy is especially disadvantageous. A stemcell-based cell culture (with a constant number of stem cells) cannot be passaged, because it requires dilution of the stem cells. Such a cell culture depends on removal of terminal (differentiated or apoptotic) cells, which otherwise accumulate. Therefore, cell cultures that have undergone multiple passages will unlikely retain any quiescent stem cells.
The stem cell hierarchy exists in vivo exactly to prevent uncontrollable growth, by separating self-renewal and proliferation. There is a strong selective pressure against the stem cell hierarchy. In vitro, if a proliferating cell loses only the ability to undergo differentiation, it will dominate and eventually replace all other cells. (Note: while losing physiological differentiation, cells may retain drug-induced differentiation). Similarly, a tumor will evolve from the stem-cell-based hierarchy to the dominance of proliferating cells. In such proliferating (non-stem) cells, drug resistance could be easily selected, yet stem cells are intrinsically resistant to therapy that kills proliferating cells.
Stem cells and therapeutic failures: assumed consensus
Despite therapeutic responses and remissions, leukemia often relapses due to residual malignant cells. 31, 32 To explain persistence of leukemia cells in remission, it has been suggested that therapy does not affect stem cells, and that killing cancer stem cells is the only truly curative approach in cancer. 1, 21, 27, 29 The consensus has emerged that resistance of quiescent tumor stem cells to current therapy contributes to persistence of residual tumor cells and eventual relapse. Even if therapy kills all proliferating cells, stem cells repopulate tumor. Then, tumor stem cells rather than 'regular' proliferating cancer cells must be attacked by cancer therapy. These ideas are not recent. For example, it was previously discussed that interferon, which targets resting cells, may be a cure in neoplasms involving stem cells and may suppress the re-emergence of tumors. 33 Although it is the quiescence of stem cells that explains why therapy fails, co-incidentally, stem cells can be drug resistant because they express drug pumps (ABC transporters). [34] [35] [36] [37] [38] Similarly, side population (SP) cancer cells express ABC transporters, rendering SP cells resistant to most chemotherapeutic agents. 39, 40 However, SP cells are not necessarily stem cells because SP cells are not quiescent. Furthermore, SP cells must renew themselves at least at the same rate as proliferating non-SP cells, otherwise SP cells will become extinct in cell culture. In other words, SP cells can be considered as dominant proliferating cells. In another study, ABCG2 (an ABC pump) expression was associated with proliferation. ABCG2-negative cancer cells can generate ABCG2-positive cells and vice versa. 40 Furthermore, ABCG2 þ and ABCGÀ cancer cells have very similar tumorigenicity. 40 The expression of drug transporters is not obligatory to define normal or cancer stem cells. Conversely, ordinary cancer cells can acquire drug transporters. Regardless of whether pump-expressing cells are cancer stem cells or just immortal cancer cells, I will also discuss the strategy to selectively kill cells that efflux drugs, because this is an important topic on its own.
How therapy fails: three scenarios
According to the stem cell-based model, therapy fails because it spares cancer stem cells (Figure 3a) . Unfortunately, for most cancers including kidney, pancreatic, and colon cancers, the problem is not that a few cells survive but, rather, that only a few cells die in response to chemotherapy. 27 The most common scenario is shown in Figure 3b . Therapy does not even cause disease stabilization. Cancer progresses despite therapy, resulting in patient death. Even if therapy works, cancer usually relapses due to therapy-resistant clones (Figure 3c ). According to scenario 3C, therapy eliminates sensitive cells, thus selecting for resistant cells. This selection often causes disease progression. For instance, in acute lymphoblastic leukemia, this selection is associated with glucorticoid insensitivity and apoptosis reluctance. 41, 42 Other examples include therapy of hormonedependent prostate cancer and follicular thyroid cancer (reviewed in Blagosklonny 43 ). The ability of the follicular thyroid cell to take up iodine permits the use of radioactive iodine for therapy. Following effective therapy, disease may relapse due to dedifferentiation of cancer cells. Similarly, following hormonal therapy, prostate cancer may relapse due to the loss of hormone dependence. Such relapses indicate disease progression to aggressive and untreatable cancers. 44 Owing to tumor progression, therapeutic responses do not necessarily improve overall survival. 45 As shown in Figure 3c , therapy spares dominant (aggressive and resistant) clones, which alone determine prognosis. The problem is not that therapy kill only proliferating cells (Figure 3a ), but that it does not actually kill all of them (Figure 3b and c).
Therapy in stem cell-dependent tumors: chronic phase CML
The chronic phase of CML is consistent with scenario 3A. BcrAbl, which is present in CML stem cells, increases proliferation and survival of non-stem progenitor myeloid (blast) cells. This is manifested by expansion of hematopoiesis with an increased 46, 47 However, the disease can relapse. One explanation is that stem cells are inherently resistant to therapy. 30 It seems that imatinib is toxic to Bcr-Abl-expressing cells in cellcycle-independent manner, 48 and that stem cells are resistant, even if they do not express Pgp. 49 Imatinib preferentially kills committed blast cells, sparing stem cells. By killing progenitor cells, imatinib effectively controls leukemia. 50 Similarly, cytostatic agents (standard therapy for CML in the pre-Gleevec era) target proliferating cells and decrease the leukemia cell burden. For example, hydroxyurea, which universally inhibits DNA synthesis, effectively controls CML. Stem cells that are quiescent are not affected by hydroxyurea. They persist and replenish leukemia cell pool (Figure 3a) . Although leukemia cannot be eradicated, unless stem cells are killed by intensive chemotherapy and donor stem cells are transplanted, cytostatic agents (e.g., hydroxyurea) still control the disease (Figure 3a ). This may be sufficient. However, the stem cell scenario (Figure 3a ) cannot last forever, because therapy selects for proliferating clones capable of self-renewal. In other words, the problem arises when proliferating cells acquire the ability for self-renewal (note: self-renewal can be achieved by losing the ability to differentiate). Proliferating cells become independent from initial stem cells and evolve independently, acquiring resistance (Figure 3c ). Among all scenarios (Figure 3 ), stem-cell-based relapse ( Figure 3a) seems to be the best scenario after all. In scenario 3A, the relapsed tumor is identical to the initial tumor. Therefore, it would respond to the same therapy. Therapy would induce a second remission as easily as the first remission. In fact, imatinib has significant activity against CML in relapse after allogeneic stem cell transplantation. 51 Stem cell-based relapse will respond to therapy
In remission, cells with mutated Bcr-Abl (that confer resistance to imatinib) persist. 29, 52 Furthermore, mutated Bcr-Abl is often detectable before therapy. 50 However, in the chronic phase of CML, imatinib does not readily select for resistance. 53 If a resistance-confirming mutation occurs in stem cells, it will persist but cannot be selected. To select for resistance, imatinib must kill stem cells with wild-type Bcr-Abl. If stem cells are inherently resistant to imatinib, then they will retain wt Bcr-Abl. In the chronic phase of CML, selection for resistance takes place among proliferating cells, but selected cells are eliminated by differentiation. If selected cells cannot renew themselves, the selection will be fruitless. There is no mechanism for how the selected progeny can retrogradely affect stem cells.
Consider a stem cell with mutant Bcr-Abl, which produces imatinib-resistant proliferating cells (all other stem cells produce sensitive progenitors). Imatinib will kill most of wild-type BcrAbl proliferating and differentiated cells, thus increasing the ratio of mutant to wild-type Bcr-Abl among non-stem cells. Among stem cells, the ratio will be unchanged. Following imatinib withdrawal, stem cells replenish wt-Bcr-Abl-expressing proliferating cells, which will be sensitive to imatinib.
Stem cell independence and therapy
Despite persistence of mutated Bcr-Abl, the disease will not become drug resistant, unless proliferating progenitors acquire the potential for self-renewal. Selection for resistance must be accompanied by disease progression towards stem cell independence (Figure 3c ).
In CML, disease progression is known as blast crisis. 24, 26 In blast crisis as well as acute leukemia, additional oncogenic mutations occur in proliferating blast cells, 25, 54 leading to transition from chronic phase to blast crisis (from stem celldependent leukemia to cell line-like leukemia ( Figure 1 vs Figure 2 ). In this event, the disease is poorly controlled by therapy because resistance of proliferating cells is selectable. Leukemic cells undergo clonal selection and become genetically heterogeneous. Self-sustained cycling leukemic cells become more 'progressed' (malignant and therapy resistant) than would be the progeny of original leukemia stem cells.
If the original stem cell repopulates the tumor, then the tumor would return to a more benign stage: from blast crisis to the chronic phase. In stem cell-based relapses (wt-Bcr-Abl), the disease will be controllable by imatinib. In contrast, relapse due to mutated Bcr-Abl will have a worse prognosis. 55 Acquiring resistance means that leukemia is sustained by self-renewal blast cells that are protected by a resistance-conferring mutation, whereas all cells without the mutation were eradicated. Thus, it is proliferating cells, not resting cells, that are the most crucial target in the advanced disease.
In advanced stages, elimination of all proliferating leukemic cells is needed to control the disease. If all proliferating leukemia blasts are eliminated, this, in theory, may result in disease regression to its chronic stage (Figure 3a) , which is well controllable. In contrast, if therapy would target resting stem cells only, it may do nothing besides yielding side effects. Finally, therapy may induce differentiation in proliferating leukemic cells, thus not only eliminating the proliferating leukemic clone but also increasing the number of functional mature cells. Retinoic acid (especially in a combination with arsenic) is capable of overcoming a differentiation block and induces clinical remissions in acute promyelocytic leukemia. 56, 57 Unfortunately, there are few (if any) clinically approved agents that cause differentiatiation in other leukemias and solid cancers. In clinical trails, phorbol ester (PMA/TPA), one of the most potent inducers of differentiation, was effective and well tolerated in patients with myelocytic leukemia. 
Target for cancer therapy: proliferating cells or stem cells MV Blagosklonny

Stem cells in brain tumors
Glioblastoma multiforme (brain cancer) contains neural precursors endowed with all of the critical features expected from neural stem cells. 13 These cells can act as tumor-founding cells and can establish tumors in animals that closely resemble the human disease. 13 However, there is no evidence that they may be responsible for tumor recurrence following therapy, because glioblastoma multiforme does not respond to therapy (Figure 4b ). Thus, therapy fails because it does not affect even proliferating cells. Only recently, it has been shown that certain brain tumors respond to use of the alkylating drug temozolomide, which preferentially targets cycling cells, especially in conjunction with radiation. 59, 60 Thus, targeting proliferating cells is the first necessary step to control cancer. In contrast, if therapy eliminates stem cells selectively, progeny cells will have enough divisions to kill a patient. Given that the tumor grows inside the brain, proliferating cells (even with limiting selfrenewal) are the most dangerous. Another question is how to selectively target tumor stem cells. They have stem cell markers such as the CD133 antigen, for instance. Of course, therapy aimed at CD133-positive cells also will affect normal neuronal stem cells. Furthermore, normal hematopoietic, endothelial, and renal stem cells also express CD133. 23, 61 A strategy to protect normal stem cells from therapy may become essential.
However, what if tumor stem cells are actively cycling? For one, they can undergo serial transplantations. 13 However, the quiescence is crucial to explain resistance of cancer stem cells to therapy in the first place.
1 If 'stem' cells proliferate faster than their daughter cells, then such cells must be targeted, just because they are proliferating cells. Maybe stem-like cells proliferate slowly enough to be therapy resistant and quickly enough to be dangerous. Even then, they are dangerous because they proliferate.
Cycle-dependent anticancer drugs
Chemotherapy, which preferentially spares resting stem cells, is curative in testicular cancer, choricarconoma, and certain childhood leukemias. [62] [63] [64] Most chemotherapeutic drugs are toxic preferentially to proliferating cells. For example, vincristine, vinblastine, paclitaxel, and docetaxel arrest cells in mitosis, thus causing cell death. DNA-damaging drugs (such as topoisomerase-I inhibitors) are preferentially cytotoxic during S phase. Definitely, microtubules and DNA topoisomerases are not unique to cancer cells. They also are present in all normal cells. In fact, chemotherapy causes severe side effects due to killing of proliferating normal cells. However, the cell cycledependent toxicity is limited to proliferating cells, whereas normal stem cells are resting. This may explain why cycledependent therapy is useful: it attacks all essential cancer cells and only a subset of normal cells.
The disadvantage of chemotherapy is not that it is cell cycledependent but is that it is not absolutely cell cycle dependent. In other words, therapy targets normal resting cells, too. Although microtubule inhibitors kill cycling cells by causing mitotic arrest, they are also toxic to neuronal cells, because microtubules are essential for axonal transport. (One might wish for drugs that are absolutely mitosis-dependent.) Still, generally, cycle-dependent chemotherapy spares resting normal cells as well as resting cancer cells.
Fast-and slow-growing tumors
In fast-growing tumors, targeting proliferating cells is imperative. There is an opinion, however, that in slow-growing tumors resting cells must be targeted, too. It was discussed that, since most cells are resting, resting cells should be targeted. Actually, this is a reminiscent of 'stem cell as a target'. As it has been pointed out, the only thing new is that the term stem cell is used to describe those cells that were previously referred to as resting in G0. 27 There may be two types of slow-growing tumors. Tumors may grow slowly because proliferation is compensated by cell death. In such apoptosis-prone tumors, targeting cycling cells may result in tumor shrinkage. In truly slow-growing tumors, most cells are neither mitotic nor apoptotic. Thus, solid cancers that contain a few proliferating cells often do not respond to standard chemotherapy. In order to shrink these slow-growing tumors, it is necessary to target resting cells. For example, anti-CD20 antibodies target both cycling and resting lymphocytes and cause response (shrinkage) in slow-growing lymphomas. 65 Yet, tumor shrinkage is not necessary to cure disease. It may be sufficient to stop tumor growth and to prevent its spreading and metastasis. Therefore, only a small proportion of tumor cells (namely, proliferating cells) needs to be targeted. If all cells that are capable of proliferating are killed, the disease is cured (even without remission or shrinkage).
Stem cells in slow-growing tumors
The notion that stem cells should be targeted in slow-growing tumors is based on a misleading analogy: namely, stem cells are It is possible to target dominant clones specifically, by exploiting their resistance to cell cycle arrest. 67 By inducing cycle arrest, cytostatic agents will protect normal cells from chemotherapy that kills proliferating cells. Figuratively, resistant cells 'resist' protection. When normal cells are protected from chemotherapy, then highly cytotoxic drugs can be safely used. For example, consider a heterogeneous tumor with a dominant clone containing mutant p53. Certain p53-inducing agents arrest the cell cycle in normal cells but not in cells with mutant p53, protecting normal cells from cytotoxicity of cycledependent chemotherapy. 68 In contrast, cancer cells with mutant p53 continue to proliferate, despite treatment with wild-type p53-inducing agents. Then, chemotherapy, that targets proliferating cells only, will selectively kill these dominant cancer cells. 67, 68 Like normal cells, cancer cells with wild-type p53 might be protected as well, yet the dominant cancer clone will be selectively eliminated.
Targeting drug-resistant cells
Is it possible to kill PgP-, MRP-or BCRP-expressing cells selectively? Usually, it is the other way around (cells not expressing these drug pumps are selectively killed), because many drugs are substrates of drug pumps. However, some cytotoxic drugs are not substrates, whereas some protective agents (such as the caspase inhibitor Z-DEVD-fms) are substrates of Pgp, for instance. Such protective agents can be combined with cytotoxic drugs that are not substrates of PgP. 69 While a cytotoxic drug induces caspase-dependent cell death in both normal and Pgp-expressing cells, its combination with Z-DEVDfmk kills Pgp-expressing cells selectively. 69 As another example, Pgp may pump out agents that arrest cell cycle, antagonizing cell-cycle-dependent chemotherapy. 70, 71 Therefore, it is possible to design a variety of drug combinations that may target SP cell populations and any drug-resistant clones, while sparing cells lacking drug pumps. 69, 71 Still normal stem cells express such pumps too. Yet, normal stem cells will be protected by their quiescence, because cycle-dependent chemotherapy spares resting cells.
Targeting stem cell pathways in cycling cancer cells
Tumor cells may either preserve or reactivate stem cell signaling pathways. 1, 72 Still, self-renewal cancer cells are not stem, unless they are quiescent. If they are cycling, then they are immortal cancer cells. (However, strictly speaking, cancer cells do not have to be immortal: a hundred divisions would be surely sufficient to maintain any tumor.) Stem cell pathways involving beta-catenin, hedgehog, or Wnt are very promising targets for anticancer drugs. 73 However, they are promising targets not because they are expressed in resting stem cells but because they are activated in cycling cancer cells. The goal is targeting stem cell pathways in cycling cells only.
There is an increasing number of observations that tumors (ovarian cancer, melanoma) contain aggressive stem-like cells. There is no indication that they are resistant to cycle-dependent therapy or (if resistant) that they are resistant because of quiescence. If these cells are cycling, then they are an important target for cancer therapy.
Targeting proliferating stem-like cells
Side effects due to killing of normal proliferating cells (e.g., hair loss and leukopenia) are usually reversible because normal stem cells are spared. Therapy that damages normal stem cells may cause irreversible side effects. Unlike differentiation markers, stem cell markers are not tissue-specific. For instance, CD133 is present not only in the brain tumor stem cell but also in normal renal and hematopoetic stem cells. 23, 61 Despite this, there is a solution. As discussed, self-renewal and proliferation normally are dissociated. Normal stem cells are quiescent most of the time. If a cell expresses stem cell markers and proliferates, then it is abnormal and should be attacked. Thus, the solution is targeting stem cell markers in cycling cells only. For a hypothetical example, an antibody against a stem cell antigen can be conjugated with an anticancer drug that is toxic only to cycling cells (either in mitosis or in S-phase). Then, the anticancer drug will be delivered only to cells with stem cell antigens and will kill only cycling cells. Normal resting stem cells will be spared.
Conclusion
It is wishful thinking that therapy fails due to survival of resting tumor stem cells. For this to occur, therapy must first kill all proliferating tumor cells. With the exception of initial stages of certain leukemias, therapy fails not because it eliminates only proliferating cells, but because it actually does not eliminate them. To control cancer, the only absolutely obligatory target of cancer therapy is the proliferating cell. To be precise, therapy can be aimed at resting cells or endothelial cells (e.g., antiangiogenic therapy) in order to affect a tumor, but it is the proliferating cancer cell that invades, metastasizes, and acquires mutations and drug resistance. Furthermore, it is the dominant clones of proliferating cancer cells that must be targeted to control cancer. Since resting and dormant cells can resume proliferation, repeated courses will certainly be required. Cancer therapy will be limited by selection for resistance and/or side effects (due to toxicity to normal cells). Then, cycledependent therapy can be combined with agents that protect normal cells while eradicating the utmost resistant cancer cellsthe precise cell population that otherwise would kill a patient.
